score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline			Copy Number	CDK4	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				CDK4 Amplification	1.0	KIRP-2Z-A9JG	TCGA-2Z-A9JG-01	
Putatively Actionable	Preclinical			Copy Number	MDM2	Amplification				0.0	0.0		Putatively Actionable	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	https://doi.org/10.1111/j.1349-7006.2010.01821.x													0				MDM2 Amplification	0.0	KIRP-2Z-A9JG	TCGA-2Z-A9JG-01	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.29						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (29%)		KIRP-2Z-A9JG		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						KIRP-2Z-A9JG		
Biologically Relevant				Copy Number	ETV6	Amplification				0.0	0.0																					0				ETV6 Amplification		KIRP-2Z-A9JG	TCGA-2Z-A9JG-01	
Biologically Relevant				Copy Number	ERBB3	Amplification				0.0	0.0																					0				ERBB3 Amplification		KIRP-2Z-A9JG	TCGA-2Z-A9JG-01	
Biologically Relevant				Copy Number	KRAS	Amplification				0.0	0.0																					0				KRAS Amplification		KIRP-2Z-A9JG	TCGA-2Z-A9JG-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		KIRP-2Z-A9JG		
